Recordati Raises Forecast for Isturisa After Smooth Launches
Peak Sales Estimate For Cushing's Drug Upped From €100m to €300-350m
The Italian firm's move to license Isturisa from Novartis last year is paying dividends already and Recordati has already tripled its peak sales forecast for the Cushing's therapy.
You may also be interested in...
Acquired from Novartis last year, Isturisa is forecast to have peak sales of over $100m. Now all eyes will be on a PDUFA date in March.
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
The coronavirus pandemic hurt the German group's healthcare division but helped the contract development and manufacturing activities of Merck's life sciences business.